MannKind (MNKD)
Market Price (5/11/2026): $3.59 | Market Cap: $1.1 BilSector: Health Care | Industry: Biotechnology
MannKind (MNKD)
Market Price (5/11/2026): $3.59Market Cap: $1.1 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Diabetes Management, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -64%, 3Y Excs Rtn is -91% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 99x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 56x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.5% Key risksMNKD key risks include [1] the potential failure of its clinical development programs, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Diabetes Management, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -64%, 3Y Excs Rtn is -91% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 99x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 56x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.5% |
| Key risksMNKD key risks include [1] the potential failure of its clinical development programs, Show more. |
Qualitative Assessment
AI Analysis | Feedback
MannKind (MNKD) stock has lost about 40% since 1/31/2026 because of the following key factors:
1. Direct Threat to Key Royalty Revenue from United Therapeutics' Tresmi.
MannKind's stock experienced a significant drop of 36.82% on February 25, 2026, following the announcement by its collaboration partner, United Therapeutics, of a new proprietary soft mist inhaler called Tresmi. This product directly competes with Tyvaso DPI, for which MannKind receives a 9% royalty on net sales, posing a substantial threat to a key revenue stream.
2. Increased Operating Expenses and Q1 Net Loss.
For the first quarter of 2026 (ending March 31, 2026), MannKind reported a GAAP net loss of $16.6 million, or $0.05 per share, which missed analyst estimates of -$0.02 per share. This loss was largely attributed to increased operating expenses, including a 56% rise in research and development expenses to $17.2 million and a 116% surge in selling, general, and administrative expenses to $54.1 million, reflecting substantial investments in pipeline development and commercialization.
Show more
1. Direct Threat to Key Royalty Revenue from United Therapeutics' Tresmi.
MannKind's stock experienced a significant drop of 36.82% on February 25, 2026, following the announcement by its collaboration partner, United Therapeutics, of a new proprietary soft mist inhaler called Tresmi. This product directly competes with Tyvaso DPI, for which MannKind receives a 9% royalty on net sales, posing a substantial threat to a key revenue stream.
2. Increased Operating Expenses and Q1 Net Loss.
For the first quarter of 2026 (ending March 31, 2026), MannKind reported a GAAP net loss of $16.6 million, or $0.05 per share, which missed analyst estimates of -$0.02 per share. This loss was largely attributed to increased operating expenses, including a 56% rise in research and development expenses to $17.2 million and a 116% surge in selling, general, and administrative expenses to $54.1 million, reflecting substantial investments in pipeline development and commercialization.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -39.1% change in MNKD stock from 1/31/2026 to 5/10/2026 was primarily driven by a -46.8% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.78 | 3.52 | -39.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 314 | 361 | 15.0% |
| P/S Multiple | 5.7 | 3.0 | -46.8% |
| Shares Outstanding (Mil) | 307 | 308 | -0.5% |
| Cumulative Contribution | -39.1% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| MNKD | -39.1% | |
| Market (SPY) | 3.6% | 17.0% |
| Sector (XLV) | -6.9% | 21.2% |
Fundamental Drivers
The -37.0% change in MNKD stock from 10/31/2025 to 5/10/2026 was primarily driven by a -46.8% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.59 | 3.52 | -37.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 302 | 361 | 19.6% |
| P/S Multiple | 5.6 | 3.0 | -46.8% |
| Shares Outstanding (Mil) | 305 | 308 | -1.1% |
| Cumulative Contribution | -37.0% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| MNKD | -37.0% | |
| Market (SPY) | 5.5% | 13.9% |
| Sector (XLV) | 0.3% | 19.0% |
Fundamental Drivers
The -30.2% change in MNKD stock from 4/30/2025 to 5/10/2026 was primarily driven by a -39.0% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.04 | 3.52 | -30.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 286 | 361 | 26.4% |
| P/S Multiple | 4.9 | 3.0 | -39.0% |
| Shares Outstanding (Mil) | 279 | 308 | -9.4% |
| Cumulative Contribution | -30.2% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| MNKD | -30.2% | |
| Market (SPY) | 30.4% | 16.6% |
| Sector (XLV) | 4.0% | 23.9% |
Fundamental Drivers
The -8.6% change in MNKD stock from 4/30/2023 to 5/10/2026 was primarily driven by a -70.4% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.85 | 3.52 | -8.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 100 | 361 | 261.6% |
| P/S Multiple | 10.2 | 3.0 | -70.4% |
| Shares Outstanding (Mil) | 263 | 308 | -14.5% |
| Cumulative Contribution | -8.6% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| MNKD | -8.6% | |
| Market (SPY) | 78.7% | 21.1% |
| Sector (XLV) | 13.0% | 26.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MNKD Return | 40% | 21% | -31% | 77% | -12% | -37% | 13% |
| Peers Return | 9% | -9% | 4% | -11% | 10% | 6% | 7% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| MNKD Win Rate | 50% | 50% | 50% | 67% | 50% | 60% | |
| Peers Win Rate | 52% | 50% | 55% | 43% | 50% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| MNKD Max Drawdown | 0% | -40% | -37% | -11% | -47% | -60% | |
| Peers Max Drawdown | -11% | -23% | -19% | -26% | -19% | -14% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACT, ALKS, LIVN, PRGO, PCRX. See MNKD Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | MNKD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -32.7% | -18.8% |
| % Gain to Breakeven | 48.5% | 23.1% |
| Time to Breakeven | 81 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -23.1% | -9.5% |
| % Gain to Breakeven | 30.0% | 10.5% |
| Time to Breakeven | 112 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.8% | -6.7% |
| % Gain to Breakeven | 42.5% | 7.1% |
| Time to Breakeven | 98 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -41.1% | -24.5% |
| % Gain to Breakeven | 69.8% | 32.4% |
| Time to Breakeven | 87 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.2% | -33.7% |
| % Gain to Breakeven | 69.9% | 50.9% |
| Time to Breakeven | 67 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -43.3% | -19.2% |
| % Gain to Breakeven | 76.5% | 23.7% |
| Time to Breakeven | 62 days | 105 days |
In The Past
MannKind's stock fell -32.7% during the 2025 US Tariff Shock. Such a loss loss requires a 48.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MNKD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -32.7% | -18.8% |
| % Gain to Breakeven | 48.5% | 23.1% |
| Time to Breakeven | 81 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -23.1% | -9.5% |
| % Gain to Breakeven | 30.0% | 10.5% |
| Time to Breakeven | 112 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.8% | -6.7% |
| % Gain to Breakeven | 42.5% | 7.1% |
| Time to Breakeven | 98 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -41.1% | -24.5% |
| % Gain to Breakeven | 69.8% | 32.4% |
| Time to Breakeven | 87 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.2% | -33.7% |
| % Gain to Breakeven | 69.9% | 50.9% |
| Time to Breakeven | 67 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -43.3% | -19.2% |
| % Gain to Breakeven | 76.5% | 23.7% |
| Time to Breakeven | 62 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -76.8% | -3.7% |
| % Gain to Breakeven | 331.8% | 3.9% |
| Time to Breakeven | 154 days | 6 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -36.6% | -17.9% |
| % Gain to Breakeven | 57.8% | 21.8% |
| Time to Breakeven | 44 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -29.3% | -15.4% |
| % Gain to Breakeven | 41.5% | 18.2% |
| Time to Breakeven | 36 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -75.8% | -53.4% |
| % Gain to Breakeven | 313.4% | 114.4% |
| Time to Breakeven | 105 days | 1085 days |
In The Past
MannKind's stock fell -32.7% during the 2025 US Tariff Shock. Such a loss loss requires a 48.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About MannKind (MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
AI Analysis | Feedback
- The Eli Lilly of inhaled insulin.
- The Dyson of inhaled drug delivery.
- Like a specialized Vertex Pharmaceuticals, but focused on inhaled treatments for endocrine and orphan lung diseases.
AI Analysis | Feedback
- Afrezza: An inhaled insulin used to improve glycemic control in adults with diabetes.
- Thyquidity: A product promoted for the treatment of hypothyroidism.
- ZYESAMI (aviptadil): A dry powder formulation under development in collaboration with NRx Pharmaceuticals to help protect cells against inflammatory conditions.
AI Analysis | Feedback
MannKind Corporation (MNKD) sells its products primarily to other companies within the healthcare supply chain and through strategic collaborations. Its major customers include:
-
Pharmaceutical Wholesalers: These companies are the primary direct purchasers of MannKind’s commercial products, such as Afrezza and Thyquidity, for distribution to pharmacies, hospitals, and other healthcare providers. The largest pharmaceutical wholesalers in the United States, which typically serve as major customers for biopharmaceutical companies, include:
- McKesson Corporation (MCK)
- Cardinal Health, Inc. (CAH)
- AmerisourceBergen Corporation (ABC)
- United Therapeutics Corporation (UTHR): As per the company description, MannKind has a license and collaboration agreement with United Therapeutics Corporation. This agreement indicates that United Therapeutics is a significant partner and customer for licensed products or services related to their collaboration.
- NRx Pharmaceuticals (NRXP): MannKind has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI. This type of development agreement often involves payments for services or future product supply, making NRx Pharmaceuticals a customer in this context.
AI Analysis | Feedback
```html- United Therapeutics Corporation (UTHR)
- Bachem AG (BANB)
- Dr. Reddy's Laboratories Ltd. (RDY)
AI Analysis | Feedback
Michael Castagna, Chief Executive Officer
Michael Castagna became CEO of MannKind Corporation and joined its board of directors in 2017, bringing over 25 years of experience in healthcare, pharmaceuticals, and biotechnology to the company's product and medical device development strategy. Prior to MannKind, he served as Vice President at Amgen, where he guided both the Lifecycle Management and Global Commercial Biosimilar business areas. He spent a combined 10 years at Bristol-Myers Squibb, focusing on medical, marketing, and sales, and also directed their Immunoscience division. His other industry experience includes serving as a Vice President at Sandoz (Novartis), where he established the U.S. Biologics Business Unit, and as a Director at Merck, Serono, Pharmasset, and DuPont Pharmaceuticals.
Christopher Prentiss, Chief Financial Officer
Christopher Prentiss was appointed Chief Financial Officer of MannKind Corporation effective April 22, 2024. He brings over two decades of financial leadership experience within the biopharma sector. Prior to joining MannKind, Mr. Prentiss served as CFO of ADARx Pharmaceuticals, where he helped facilitate a funding round of nearly $250 million. His professional history also includes a tenure as CFO at Adamas Pharmaceuticals, where he contributed to significant company milestones such as product launches and revenue growth.
Dominic Marasco, President, Endocrine Business Unit
Dominic Marasco joined MannKind Corporation as President, Endocrine Business Unit, effective January 6, 2025. He has over 25 years of experience in driving commercial success within the biopharma and biotech sectors. Mr. Marasco previously held the position of Executive President, Chief Commercial Officer for Envision Pharma Group, and prior to that, he was Chief Commercial Officer at BioAgilytix Labs, Inc. His background also includes leadership roles at Syneos Health, Amgen, and Sandoz Biopharmaceuticals.
Ajay Ahuja, Executive Vice President and Chief Medical Officer
Dr. Ajay Ahuja joined MannKind Corporation as Executive Vice President and Chief Medical Officer in 2025, with his appointment effective September 29, 2025. A pediatrician and cardiologist, Dr. Ahuja is a seasoned biopharmaceutical leader with over two decades of industry experience. His expertise spans medical devices, drug delivery platforms, and biopharmaceuticals, particularly in therapeutic areas such as diabetes, cardiovascular disease, respiratory medicine, and infectious diseases. Before MannKind, Dr. Ahuja held leadership roles in clinical development, medical affairs, and commercial strategy at companies including Kardigan Bio, Takeda, Pfizer, GSK, and Novartis.
Sanjay Singh, Executive Vice President, Technical Operations
Sanjay Singh is MannKind's Executive Vice President of Technical Operations, leading the company's Danbury facility and overseeing commercial and contract manufacturing. He brings over 30 years of experience in pharmaceutical technical operations, having worked with multiple technologies, delivery systems, and therapeutic areas. Prior to joining MannKind in 2022, Mr. Singh was Associate President of Operations for Aurobindo Pharma USA and served as Senior VP of Operations for Aurobindo Pharma India.
AI Analysis | Feedback
The key risks to MannKind Corporation (MNKD) include the following, listed in order from most significant to least significant:
- Dependence on United Therapeutics and Competition from New Products: MannKind is heavily reliant on its collaboration with United Therapeutics, particularly for royalties derived from Tyvaso DPI. A significant and immediate risk is United Therapeutics' recent unveiling of Tresmi, a soft-mist treprostinil inhaler, which has been described as a "category killer product" and could potentially compete with or replace Tyvaso DPI. This development introduces uncertainty regarding the long-term durability of MannKind's Tyvaso DPI royalties, a key revenue stream.
- Regulatory and Market Adoption Challenges for Products: As a biopharmaceutical company, MannKind faces ongoing regulatory risks. Immediate risks include upcoming FDA decisions on the Afrezza pediatric sBLA in May 2026 and the Furoscix ReadyFlow Autoinjector sNDA in July 2026. Delays or negative outcomes in these regulatory processes could materially impact near-term growth expectations. Historically, Afrezza has also encountered significant market adoption hurdles, including issues with insurance coverage and the requirement for lung function tests, which could recur with new product introductions or expanded indications.
- Need for Additional Capital and Financial Health: MannKind has a history of requiring additional capital to fund its operations, research and development activities, and commercialization efforts. Despite recent initiatives like a sale-leaseback transaction to generate capital, indicators such as a low Altman Z-Score suggest an elevated financial distress risk and highlight that interest payments are not consistently well covered by earnings. The company must continuously manage its financial health and access to capital to support its growth strategy and ongoing operations.
AI Analysis | Feedback
null
AI Analysis | Feedback
MannKind Corporation's primary products, Afrezza and Thyquidity, operate within addressable markets of significant size. Information regarding the addressable market for their collaboration product, ZYESAMI, is not available. * **Afrezza (Inhaled Insulin)** The global inhalable insulin market was valued at USD 630 million in 2024 and is projected to reach USD 1,476.10 million by 2032. Within North America, the inhaled insulin market was valued at USD 237.51 million in 2024 and is expected to reach approximately USD 1,012.83 million by 2034. The U.S. inhalable insulin market held the largest revenue share of 77.9% within North America in 2024. The broader global non-injectable insulin market, which includes inhalable insulin, is estimated at USD 1.7 billion in 2024 and is projected to reach USD 6.1 billion by 2034. * **Thyquidity (Hypothyroidism Treatment)** The global thyroid gland disorder treatment market was valued at USD 2.22 billion in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.6% from 2024 to 2030. Hypothyroidism was the dominant segment within this market, accounting for a 68.7% share in 2023. North America led the global thyroid gland disorder treatment market with a revenue share of over 35.44% in 2023, with the U.S. market alone accounting for 29.4% of the global market in the same year. Additionally, the 7 major hypothyroidism markets (United States, EU4, UK, and Japan) collectively reached USD 1.6 billion in 2024 and are anticipated to grow to USD 2.3 billion by 2035. The global hypothyroidism market is projected to reach USD 1,817.13 million (approximately USD 1.82 billion) by 2030. * **ZYESAMI (aviptadil)** nullAI Analysis | Feedback
MannKind (MNKD) is expected to drive future revenue growth over the next 2-3 years through several key areas:
- Continued Growth in Tyvaso DPI Royalties and Collaboration Revenue: MannKind's collaboration with United Therapeutics for Tyvaso DPI, an inhaled therapy for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, continues to be a significant revenue driver. The company receives royalties on net sales of Tyvaso DPI and revenue from its manufacturing activities. Strong patient demand for this product has consistently driven increased revenue, with MannKind anticipating receiving between $700 million and $1 billion in cash from Tyvaso over the next few years.
- Expansion and Demand for Afrezza: Afrezza, MannKind's inhaled insulin product, is expected to see continued revenue growth driven by increasing patient demand, favorable pricing strategies, and improved gross-to-net adjustments. A significant anticipated catalyst is the potential FDA approval for a pediatric indication, with a decision expected by May 29th, 2026. Additionally, an FDA label update to simplify switching from injected insulin is expected to further support its adoption. International expansion efforts are also contributing to Afrezza's growth.
- Growth of FUROSCIX with Autoinjector Launch: Following the acquisition of scPharmaceuticals, FUROSCIX has become a key growth engine within MannKind's cardiometabolic franchise. The anticipated approval of the FUROSCIX ReadyFlow Autoinjector, with a PDUFA date of July 26th, 2026, is considered a major catalyst. This autoinjector is expected to significantly expand market reach, particularly within hospitals, and accelerate sales growth, with MannKind aiming for FUROSCIX revenues in the range of $110 million to $120 million in 2026.
- Advancement of Orphan Lung Disease Pipeline (MNKD-101 and MNKD-201): MannKind is actively advancing its pipeline products for orphan lung diseases. MNKD-101 (clofazimine inhalation suspension for NTM lung disease) is progressing into a global Phase 3 clinical trial. Furthermore, MNKD-201 (nintedanib DPI for Idiopathic Pulmonary Fibrosis - IPF) has successfully completed Phase 1 studies and is on track for further clinical development, including Phase 2/3 trials. Successful development and potential commercialization of these pipeline assets represent future revenue opportunities.
AI Analysis | Feedback
Share Issuance
- MannKind reached agreements in December 2024 to exchange approximately $193.7 million of its convertible senior notes for 26,749,559 shares of common stock and about $89.2 million in cash.
- The number of shares issued and outstanding increased from 302,959,782 as of December 31, 2024, to 307,832,587 as of December 31, 2025.
- Shares outstanding (diluted average) grew by 10.39% to $313.3 million in 2025 from $283.8 million in 2024, and by 6.3% in 2024 from $267.0 million in 2023.
Inbound Investments
- MannKind receives royalties from United Therapeutics for the sales of Tyvaso DPI, leveraging MannKind's Technosphere drug delivery technology.
- The company anticipates receiving $700 million to $1 billion in cash from Tyvaso over the next few years.
- A minimum supply agreement with United Therapeutics is expected to provide approximately $100 million in revenue for 2025 and 2026, and about $50 million annually thereafter, ensuring a predictable cash flow.
Outbound Investments
- MannKind successfully completed the acquisition of scPharmaceuticals Inc. in October 2025.
- This acquisition is projected to diversify and accelerate MannKind's double-digit revenue growth, primarily driven by FUROSCIX.
Capital Expenditures
- Capital expenditures for MannKind were $4.57 million in 2025, $9.69 million in 2024, and $42 million in 2023.
- In Q4 2025, capital expenditures amounted to $2.0 million.
- Capital expenditures absorb a significant portion of operating cash flow, contributing to a low free cash flow margin of 3.9%.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| MannKind Earnings Notes | 12/16/2025 | |
| Can MannKind Stock Hold Up When Markets Turn? | 10/17/2025 | |
| MannKind (MNKD) Revenue Comparison | 08/08/2025 | |
| MannKind (MNKD) Net Income Comparison | 08/08/2025 | |
| MannKind (MNKD) Operating Cash Flow Comparison | 08/08/2025 | |
| MannKind (MNKD) Operating Income Comparison | 08/08/2025 | |
| MannKind (MNKD) Debt Comparison | 08/08/2025 | |
| MannKind (MNKD) EBITDA Comparison | 08/08/2025 | |
| MannKind (MNKD) Tax Expense Comparison | 08/08/2025 | |
| Why MannKind Stock Moved: MNKD Stock Has Gained 60% Since 2023 Fiscal End, Primarily Due To Favorable Change In Revenues | 08/08/2025 | |
| ARTICLES | ||
| Stocks Trading At 52-Week Low | 03/26/2026 |
Trade Ideas
Select ideas related to MNKD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 29.07 |
| Mkt Cap | 2.8 |
| Rev LTM | 1,337 |
| Op Inc LTM | 192 |
| FCF LTM | 147 |
| FCF 3Y Avg | 173 |
| CFO LTM | 217 |
| CFO 3Y Avg | 230 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.9% |
| Rev Chg 3Y Avg | 7.5% |
| Rev Chg Q | 9.7% |
| QoQ Delta Rev Chg LTM | 2.2% |
| Op Inc Chg LTM | -50.9% |
| Op Inc Chg 3Y Avg | 79.2% |
| Op Mgn LTM | 6.4% |
| Op Mgn 3Y Avg | 9.8% |
| QoQ Delta Op Mgn LTM | -1.0% |
| CFO/Rev LTM | 16.8% |
| CFO/Rev 3Y Avg | 18.2% |
| FCF/Rev LTM | 12.7% |
| FCF/Rev 3Y Avg | 15.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.8 |
| P/S | 2.9 |
| P/Op Inc | 30.3 |
| P/EBIT | 24.2 |
| P/E | 22.9 |
| P/CFO | 12.3 |
| Total Yield | 1.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 6.6% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.4% |
| 3M Rtn | 1.4% |
| 6M Rtn | 5.7% |
| 12M Rtn | 4.1% |
| 3Y Rtn | 1.9% |
| 1M Excs Rtn | -1.6% |
| 3M Excs Rtn | -5.4% |
| 6M Excs Rtn | 0.4% |
| 12M Excs Rtn | -27.8% |
| 3Y Excs Rtn | -70.4% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| BLA022472 | AFREZZA | insulin recombinant human | powder | 6272014 | -39.0% | -43.4% | -41.8% | -87.5% | -93.0% |
Price Behavior
Price Behavior
| Market Price | $3.52 | |
| Market Cap ($ Bil) | 1.1 | |
| First Trading Date | 07/28/2004 | |
| Distance from 52W High | -43.3% | |
| 50 Days | 200 Days | |
| DMA Price | $2.73 | $4.60 |
| DMA Trend | down | down |
| Distance from DMA | 29.0% | -23.5% |
| 3M | 1YR | |
| Volatility | 102.3% | 72.1% |
| Downside Capture | 0.32 | 0.35 |
| Upside Capture | -176.57 | 16.43 |
| Correlation (SPY) | 12.8% | 15.0% |
MNKD Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.47 | 1.48 | 1.01 | 0.72 | 0.89 | 0.76 |
| Up Beta | 1.44 | 2.01 | 1.89 | 1.39 | 1.28 | 0.56 |
| Down Beta | 15.33 | 1.49 | 1.45 | 0.53 | 0.85 | 0.79 |
| Up Capture | 120% | 46% | -95% | -39% | 11% | 40% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 14 | 19 | 29 | 55 | 114 | 350 |
| Down Capture | 430% | 207% | 196% | 130% | 119% | 102% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 8 | 22 | 33 | 61 | 126 | 371 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNKD | |
|---|---|---|---|---|
| MNKD | -25.9% | 72.1% | -0.09 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 23.1% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 16.1% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | 15.7% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -6.0% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 15.5% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 4.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNKD | |
|---|---|---|---|---|
| MNKD | -4.0% | 59.6% | 0.17 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 31.2% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 31.5% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 10.6% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 4.7% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 29.4% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 13.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MNKD | |
|---|---|---|---|---|
| MNKD | -6.1% | 83.6% | 0.29 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 21.8% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 22.8% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 5.6% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 8.0% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 18.2% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 9.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | -7.4% | -15.7% | -34.3% |
| 11/5/2025 | 10.6% | -4.2% | 3.6% |
| 8/6/2025 | -13.2% | -8.3% | 33.8% |
| 5/8/2025 | -4.5% | -5.8% | -9.7% |
| 2/26/2025 | -4.4% | -5.9% | -6.8% |
| 11/7/2024 | -0.6% | -5.0% | -9.9% |
| 8/7/2024 | -4.9% | -3.8% | 14.4% |
| 5/8/2024 | -2.0% | 1.1% | 6.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 13 |
| # Negative | 13 | 14 | 11 |
| Median Positive | 4.9% | 11.1% | 17.8% |
| Median Negative | -4.5% | -6.9% | -9.9% |
| Max Positive | 18.5% | 35.3% | 42.5% |
| Max Negative | -13.2% | -39.5% | -37.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Development Milestone Payments | 35.00 Mil | ||||||
| 2026 Royalties | 0.1 | ||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Castagna, Michael | Chief Executive Officer | Direct | Buy | 3102026 | 2.59 | 100,000 | 259,000 | 6,671,609 | Form |
| 2 | Tross, Stuart A | Chief People & Workpl Officer | Direct | Sell | 1092026 | 6.33 | 47,006 | 297,548 | 6,235,094 | Form |
| 3 | Castagna, Michael | Chief Executive Officer | Direct | Sell | 12192025 | 6.01 | 65,804 | 395,482 | 15,053,800 | Form |
| 4 | Castagna, Michael | Chief Executive Officer | Direct | Sell | 12162025 | 6.00 | 21,310 | 127,860 | 15,028,752 | Form |
| 5 | Castagna, Michael | Chief Executive Officer | Direct | Sell | 12162025 | 6.00 | 20,806 | 124,836 | 15,028,752 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.